Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab.
Schulze
J
J
Rose
M
M
Zielen
S
S
D000293:Adolescent; D000707:Anaphylaxis / Q000276:immunology* / Q000517:prevention & control*; D000818:Animals; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001516:Bees / Q000276:immunology; D003888:Desensitization, Immunologic / Q000379:methods*; D006801:Humans; D007299:Insect Bites and Stings / Q000276:immunology*; D008297:Male; D000069444:Omalizumab; D016896:Treatment Outcome
D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab